Lee, W.S. (2004) The use of infliximab in South-east Asian children with severe Crohn's disease. Pediatrics International, 46 (2). pp. 198-201. ISSN 1328-8067, DOI https://doi.org/10.1046/j.1442-200x.2004.01870.x.
Full text not available from this repository.Abstract
Childhood Crohn's disease (CD) has a chronic relapsing course with a high morbidity which includes delayed puberty, impaired growth, and perianal disease1. It is most prevalent in North America, North-west Europe, and in the United Kingdom, and is rare in Asia1. Many children with CD eventually need corticosteroid to control symptoms1. Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which is important in the pathogenesis of CD2. Infliximab (Remicade, Schering-Plough, Kenilworth, New Jersey, USA), a chimeric anti-TNFα monoclonal antibody, induces remission in patients with moderately to severely active CD and can reduce corticosteroid requirements3. We share our experience in the use of infliximab in three South-east Asian children with severe CD.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | Crohn's disease;infliximab;perianal disease |
| Subjects: | R Medicine R Medicine > RJ Pediatrics |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms Haslinda Lahuddin |
| Date Deposited: | 10 Jul 2014 01:03 |
| Last Modified: | 10 Jul 2014 01:03 |
| URI: | http://eprints.um.edu.my/id/eprint/10915 |
Actions (login required)
 |
View Item |
